The effect of leukotriene receptor antagonists adding to asthma therapy

After 1 month, 2 months and 3 months trials demonstrated that day time and night time symptoms, need for inhaled |beta2-agonist were found reduced, FEV1 (%20) and PEF (%22) values increased significantly (p

📌 3 Key Takeaways

🎯

Objective & Hypothesis:Asthma is a chronic inflamatory disease and corticosteroids are the mostly used antiinflamatory agents in asthma treatment.

📊

Key Findings & Data:Montelukast (10mg/gun) was added to the maintenance therapy of 60 patients with chronic asthma for a duration of 3 months and the findings of last 3 months period without the drug and the period of drug use were compared.

💡

Conclusion & Impact:After 1 month, 2 months and 3 months trials demonstrated that day time and night time symptoms, need for inhaled |beta2-agonist were found reduced, FEV1 (%20) and PEF (%22) values increased significantly (p

🔬Design:Research Article

📍Scope:Comprehensive Sample

⚙️Variables:Domain Parameters

Abstract

Asthma is a chronic inflamatory disease and corticosteroids are the mostly used antiinflamatory agents in asthma treatment. However they don't have an effect -on leukotrienes which have an important role in asthma pathogenesis. İn the recent years there's an improvement in the outcomes of asthma management by the use of leukotriene antagonists in clinical practice. The present clinical trial was performed to investigate effectiveness of leukotriene receptor antagonist montelukast in asthma management. Montelukast (10mg/gun) was added to the maintenance therapy of 60 patients with chronic asthma for a duration of 3 months and the findings of last 3 months period without the drug and the period of drug use were compared. Furthermore the side effects of the drug were determined. 16 of the patients were excludedand and total 44 patients with asthma (mild persistent 22, moderate persistent 19, and severe 3) were evaluated. After 1 month, 2 months and 3 months trials demonstrated that day time and night time symptoms, need for inhaled |beta2-agonist were found reduced, FEV1 (%20) and PEF (%22) values increased significantly (p

Özet

Kronik inflamatuar bir hastalık olan astma tedavisinde en sık kullanılan antiinflamatuar ilaç kortikosteroidlerdir. Ancak kortikosteroidlerin astma patogenezinde önemli' rolü olan lökotrienler üzerine etkileri yoktur. Son yıllarda klinik kullanıma giren lökotrien antagonistleri ile astma tedavisinde olumlu sonuçlar alınmaktadır. Bu çalışma bir lökotrien reseptör antagonisti olan montelukastın astma tedavisindeki etkinliğini araştırmak amacıyla planlanmıştır. Astma bronşiale tanısı ile izlenen 60 olguya almakta oldukları idame tedaviye 3 ay süreyle montelukast (lOmg/gün) eklenmiş, ilaca başlamadan önceki son 3 ay ve ilacı kullandığı dönemdeki bulgular karşılaştırılmış, ilaca bağlı yan etkiler belirlenmiştir. 1.6 olgu çalışma dışı bırakılmış; toplam 44 astmalı olgu (hafif persistan 22, orta persistan 19, ağır 3) değerlendirilmiştir. İlaca başladıktan l ay, 2 ay ve 3 ay sonra yapılan kontrollerde ilaç öncesi döneme göre istatistiksel olarak anlamlı derecede gece ve gündüz semptomları ile beta2-agonist gereksinimi azalmış, solunum fonksiyon testi (SFT) değerleri ise [(FEV1 (%20) ve PEF (%22)] artmıştır (p

🔖

Cite This Article

ÇELİKTEN, E., DEMİR, A., TAŞDÖĞEN, N., HASSOY, C., YAPICIOĞLU, S., BÜYÜKŞİRİN, M. (2022). The effect of leukotriene receptor antagonists adding to asthma therapy. Anadolu Tıp Dergisi, Cilt: 5 - Sayı: 2, 73–79. https://ajindex.com/articles/438109

References (19)

Alvarez J. Leukotriene modifiers in the treatment of asthma. Rev Alerg Mex 1999;46:72-7
Astım Ulusal Tanı ve Tedavi Kılavuzu. Koordinatör Toraks Derneği. Toraks Derneği Astım Çalışma Grubu. İstanbul, 2000
Barnes NC. The role of leukotriene receptor antagonists in the management of asthma. Eur Respir Rev 1998;8:356-7
Barnes PJ, Godfrey S. Asthma therapy. 1st ed. London: Martin Dunitz ltd; 1998:119-34
Blake KV. Montelukast: data from clinical trials in the management of asthma. Ann Pharmacother 1999;33:1299-314
D'Urzo AD, Chapman KR. Leukotriene receptpr antagonists.Role in asthma management. Can Fam Physician 2000;46:872-9
Garcia-Marcos L, Schuster A. New perspectives for asthma treatment: anti-leukotriene drugs. Pediatr Allergy Immunol 1999;10:77-88
Global initiative for asthma (GINA). Global strategy for asthma management and prevention. NHLBI/WHO workshop report. National Institute of Health. National Heart, Lung, and Blood Institute. Publication No:95-3659, May 1996
Jarvis B, Markham A. Montelukast: a review of its therapeutic potential in persistent asthma: Drugs 2000;59:891-928
Knorr B, Matz J, Bernstein JA et al. Montelukast for chronic asthma in 6- to 14- year-old children. Jama 1998;279:1181-6
Markham A, Faulds D. Montelukast. Drugs 1998;56:251-6
Oğuzülgen İK, Türktaş H, Erbaş D. Adding Montelukast to Inhaled Corticosteroids in Stepwise Approach for Managing Asthma. Turkish Respiratory Journal 2001;2(3): 16-21
Pizzichini E, Leff JA, Reiss TF et al. Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial. Eur Respir J 1999;14:12-8
Price D. Tolerability of montelukast. Drugs 2000;59 Suppl 1:35-42; discussion 43-5
Reiss TF, Chervinsky P, Dockhorn RJ et al.Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma. Arch Intern Med. 1998;158:1213-20
Salvi SS, Krishna MT, Sampson AP, Holgate ST. Chest 2001;l 19:1533-46
Spahn JD, Fost D, Szefler SJ. Leukotriene modifying agents in the treatment of asthma. In: Neffen HE, Baena CE, Fabbri L et al. Asthma- A link between environment, immunology, and the airways. World Congress of Asthmology (16th:1999: Buenos Aires); 54-61
Storms W, Michele T, Knorr B et al. Clinical safety and tolerability of montelukast, a leukotriene receptor antagonist, in controlled clinical trials in patients aged >/= 6 years. Clin Exp Allergy 2001;31:77-87
Şenyiğit A, Gürkan F